NeuroOne Medical Technologies (NMTC) Earnings Analysis
NeuroOne Medical Technologies (NMTC) next reports earnings on 2026-08-13, consensus EPS -0.58333 USD. Last quarter (2026-02-17) it beat with EPS -0.18 USD vs -0.24 USD est (+25%). It has beaten estimates in 2/5 recent quarters (40%). Trailing P/E -2.22.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does NMTC next report earnings?
| Next earnings date | 2026-08-13 |
|---|---|
| Consensus EPS estimate | -0.58333 USD |
| Revenue estimate | 0.00B |
NMTC earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-17 | -0.18 USD | -0.24 USD | +25% | Beat |
| 2025-12-17 | -0.05 USD | -0.04 USD | -25% | Miss |
| 2025-08-14 | -0.03 USD | -0.05 USD | +40% | Beat |
| 2024-12-17 | -0.11 USD | -0.09 USD | -22.2% | Miss |
| 2024-08-14 | -0.1 USD | -0.09 USD | -11.1% | Miss |
Beat rate: 2/5 (40%) over reported quarters with consensus data.
NMTC valuation and analyst view
| Trailing P/E | -2.22 |
|---|---|
| Trailing EPS | -0.78752 USD |
| Price / book | 3.03 |
| Dividend yield | 0.00% |
| Market cap | 0.02B |
| Analyst consensus | Buy (2 buy / 1 hold / 0 sell) |
| Avg price target | 3 USD |
Related research pages
Frequently asked questions
When is NeuroOne Medical Technologies (NMTC)'s next earnings date?
NeuroOne Medical Technologies is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.58333 USD and revenue estimate of 0.00B.
Did NMTC beat earnings last quarter?
In its 2026-02-17 report, NMTC posted EPS of -0.18 USD versus a -0.24 USD estimate — a beat of 25%.
What is NMTC's earnings track record?
Over the last 5 reported quarters with consensus data, NMTC beat estimates 2 times (40%).
What is NMTC's current P/E ratio and EPS?
NMTC trades at a trailing P/E of -2.22 on trailing EPS of -0.7875205751243635 USD.
What do analysts rate NMTC?
Analyst consensus is "Buy" across 3 ratings (0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 3 USD.